Form 4: Acasti Pharma Inc.: Principal Financial Officer Receives Stock Options

Robert J. DelAversano, Principal Financial Officer of Acasti Pharma Inc., was granted stock options for 4,500 Class A Common Shares on May 6, 2024.

Summary

• On May 6, 2024, Robert J. DelAversano, the Principal Financial Officer of Acasti Pharma Inc., received stock options.
• These options grant him the right to buy 4,500 Class A Common Shares at an exercise price of $2.96.
• The stock options were granted under the Acasti Pharma Stock Option Plan.
• The options vest quarterly in equal installments over a 36-month period.
• The options expire on May 6, 2034.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a stock option grant. The sentiment is slightly positive as it indicates continued investment in the company's leadership.

Positives

• The grant of stock options to the Principal Financial Officer aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize executives and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the pharmaceutical industry, similar to companies like Amarin Corporation and BioMarin Pharmaceutical.
• The vesting schedule of 36 months is also a standard practice to ensure long-term commitment.

Stakeholder Impact

• The stock option grant could potentially impact shareholders by diluting equity if the options are exercised.
• It incentivizes the Principal Financial Officer to work towards increasing shareholder value.

Key Dates